Nitay Ad‐El
YOU?
Author Swipe
View article: Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma
Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma Open
Ionizable Lipid Nanoparticles (LNP) are an FDA-approved non-viral RNA delivery system, though their use for brain therapy is restricted by the blood-brain barrier (BBB). Focused ultrasound combined with microbubbles can disrupt the BBB, bu…
View article: Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma
Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma Open
Ionizable Lipid Nanoparticles (LNPs) are an FDA-approved non-viral RNA delivery system, though their use for brain therapy is restricted by the blood-brain barrier (BBB). Focused ultrasound combined with microbubbles can disrupt the BBB, b…
View article: Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer
Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer Open
Squamous cell carcinomas of the head and neck (HNSCC) originate in the upper aerodigestive tract, including the oral cavity, pharynx, and larynx. Current treatments of locally advanced HNSCC often lead to high treatment failure, and diseas…
View article: Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects Open
Harnessing mRNA-lipid nanoparticles (LNPs) to treat patients with cancer has been an ongoing research area that started before these versatile nanoparticles were successfully used as COVID-19 vaccines. Currently, efforts are underway to ha…
View article: A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium
A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium Open
Messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines have emerged as an effective vaccination strategy. Although currently applied toward viral pathogens, data concerning the platform’s effectiveness against bacterial pathogens are limit…
View article: An Effective mRNA-LNP Vaccine Against the Lethal Plague Bacterium
An Effective mRNA-LNP Vaccine Against the Lethal Plague Bacterium Open
Plague is a rapidly deteriorating contagious disease that has killed millions of people during the history of mankind and is caused by the gram-negative bacterium Yersinia pestis . Currently, the disease is treated effectively with antibio…
View article: Burns in the Military Setting—Analyzing 12,799 Routine and Combat Cases
Burns in the Military Setting—Analyzing 12,799 Routine and Combat Cases Open
Burns are a major trauma source in civilian and military settings, with a huge impact on patient’s well-being, health system, and operation status of the force in the military setting. The purpose of our study was to summarize characterist…